Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38,077 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and characterization of a novel anti-OX40 antibody for potent immune activation.
Kuang Z, Jing H, Wu Z, Wang J, Li Y, Ni H, Zhang P, Wu W, Wu M, Zhou S, Qiu X, Wu D, Prinz B, Baruah H, Chen B, Yu M, Liu J. Kuang Z, et al. Among authors: wu w, wu d, wu m, wu z. Cancer Immunol Immunother. 2020 Jun;69(6):939-950. doi: 10.1007/s00262-020-02501-2. Epub 2020 Feb 20. Cancer Immunol Immunother. 2020. PMID: 32078015 Free PMC article.
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity.
Wang Y, Ni H, Zhou S, He K, Gao Y, Wu W, Wu M, Wu Z, Qiu X, Zhou Y, Chen B, Pan D, Huang C, Li M, Bian Y, Yang M, Miao L, Liu J. Wang Y, et al. Among authors: wu w, wu m, wu z. Cancer Immunol Immunother. 2021 Feb;70(2):365-376. doi: 10.1007/s00262-020-02679-5. Epub 2020 Aug 6. Cancer Immunol Immunother. 2021. PMID: 32761423 Free PMC article.
Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
Ni H, Cao L, Wu Z, Wang L, Zhou S, Guo X, Gao Y, Jing H, Wu M, Liu Y, Ding J, Zhang P, Zhou Y, Chen B, Xiong Y, Sun J, Prinz B, Baruah H, Geoghegan J, Yu M, Wu W, Liu J. Ni H, et al. Among authors: wu w, wu m, wu z. Cancer Immunol Immunother. 2022 Feb;71(2):353-363. doi: 10.1007/s00262-021-02989-2. Epub 2021 Jun 24. Cancer Immunol Immunother. 2022. PMID: 34165607 Free PMC article.
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
Jiang H, Ni H, Zhang P, Guo X, Wu M, Shen H, Wang J, Wu W, Wu Z, Ding J, Tang R, Zhou S, Chen B, Yu M, Jing H, Liu J. Jiang H, et al. Among authors: wu w, wu m, wu z. Oncoimmunology. 2021 Jun 24;10(1):1943180. doi: 10.1080/2162402X.2021.1943180. eCollection 2021. Oncoimmunology. 2021. PMID: 34239776 Free PMC article.
Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
Zou J, Li L, Zheng P, Liang W, Hu S, Zhou S, Wang Y, Zhao J, Yuan D, Liu L, Wu D, Xu M, Zhang F, Zhu M, Wu Z, Cao X, Ni M, Ling X, Wu Y, Kuang Z, Hu M, Li J, Li X, Guo X, Xu T, Jiang H, Gao C, Yu M, Liu J, Zhong N, Zhou J, Huang JA, Jin T, He J. Zou J, et al. Among authors: wu y, wu d, wu z. J Clin Invest. 2022 Feb 15;132(4):e154987. doi: 10.1172/JCI154987. J Clin Invest. 2022. PMID: 35108220 Free PMC article.
38,077 results
You have reached the last available page of results. Please see the User Guide for more information.